SCHEMBL945293

SCHEMBL945293

CCCNC(=O)N1CCC(CCOc2ccc(C(=O)N(C)C3C4CC5CC3CC(O)(C5)C4)cc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.43
HSD11B1 P28845 1/20 0.42
CYP2C19 P33261 2/20 0.39
MCHR1 Q99705 2/20 0.38
TEAD1 P28347 1/20 0.38
TEAD3 Q99594 1/20 0.38
MEN1 O00255 1/20 0.37
CYP2C9 P11712 1/20 0.37
KMT2A Q03164 1/20 0.37
HPGD P15428 1/20 0.37
MAPT P10636 1/20 0.36
TPSAB1 Q15661 1/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HRH2 P25021 1/20 0.35
HRH1 P35367 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL242303 0.93 HSD11B1 (0.42) GPR119HSD11B1CYP2C19MCHR1MEN1
SCHEMBL945292 0.88 GPR119 (0.47) GPR119HSD11B1MCHR1TEAD1TEAD3
SCHEMBL3632575 0.87 GPR119 (0.47) GPR119HSD11B1MCHR1TEAD1TEAD3
SCHEMBL946688 0.87 MAPT (0.43) HSD11B1MAPT
SCHEMBL942710 0.85 GPR119 (0.47) GPR119HSD11B1MCHR1TEAD1TEAD3
SCHEMBL946689 0.83 GPR119 (0.45) GPR119HSD11B1MCHR1TEAD1TEAD3
SCHEMBL944330 0.81 GPR119 (0.45) GPR119HSD11B1MCHR1SMN1; SMN2
SCHEMBL238436 0.80 GPR119 (0.44) GPR119HSD11B1MCHR1HRH2HRH1
SCHEMBL14097603 0.78 GPR119 (0.43) GPR119MCHR1TEAD1TEAD3HRH2
SCHEMBL943500 0.77 HSD11B1 (0.44) GPR119HSD11B1TEAD1TEAD3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003852-A1 N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE HIGH POINT PHARMACEUTICALS, LLC 2011-01-06 US claimed
US-20110003852-A1 N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE HIGH POINT PHARMACEUTICALS, LLC 2011-01-06 US disclosed
US-20110003856-A1 N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE HIGH POINT PHARMACEUTICALS, LLC 2011-01-06 US disclosed
EP-2146952-A1 N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE High Point Pharmaceuticals, LLC (US) 2010-01-27 EP disclosed
EP-2125704-A1 N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE High Point Pharmaceuticals, LLC (US) 2009-12-02 EP disclosed
WO-2008101885-A1 N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE HIGH POINT PHARMACEUTICALS, LLC (US) 2008-08-28 WO disclosed
WO-2008101886-A1 N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE HIGH POINT PHARMACEUTICALS, LLC (US) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003856-A1 N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE HSD11B1, HSD3B1, HSD17B1 GPR119 453/4885HSD11B1 1/4885CYP2C19 311/4885
US-20110003852-A1 N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE HSD11B1, HSD3B1, HSD17B1 GPR119 453/4885HSD11B1 1/4885CYP2C19 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.